CHICAGO — Ivosidenib extended median OS more than three times longer than placebo when added to azacitidine for adults with treatment-naive, IDH1-mutated acute myeloid leukemia, according to updated results of the phase 3 AGILE trial.The long-term follow-up data, presented at ASCO Annual Meeting, showed an additional 5-month increase in median OS with the ivosidenib (Tibsovo, Servier)